Tisdag 15 Juli | 23:22:25 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-17 08:00 Kvartalsrapport 2025-Q2
2025-06-25 - Årsstämma
2025-06-05 - X-dag ordinarie utdelning HNSA 0.00 SEK
2025-04-24 - Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-10-17 - Kvartalsrapport 2024-Q3
2024-07-18 - Kvartalsrapport 2024-Q2
2024-06-28 - X-dag ordinarie utdelning HNSA 0.00 SEK
2024-06-27 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-02 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-20 - Kvartalsrapport 2023-Q2
2023-06-15 - X-dag ordinarie utdelning HNSA 0.00 SEK
2023-06-14 - Årsstämma
2023-04-20 - Kvartalsrapport 2023-Q1
2023-02-02 - Bokslutskommuniké 2022
2022-10-20 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-06-17 - X-dag ordinarie utdelning HNSA 0.00 SEK
2022-06-16 - Årsstämma
2022-04-21 - Kvartalsrapport 2022-Q1
2022-02-03 - Bokslutskommuniké 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-14 - X-dag ordinarie utdelning HNSA 0.00 SEK
2021-05-12 - Årsstämma
2021-04-22 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-06-24 - X-dag ordinarie utdelning HNSA 0.00 SEK
2020-06-23 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-06 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning HNSA 0.00 SEK
2019-05-22 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-08 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-07-19 - Kvartalsrapport 2018-Q2
2018-05-30 - X-dag ordinarie utdelning HNSA 0.00 SEK
2018-05-29 - Årsstämma
2018-04-25 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-12-22 - Extra Bolagsstämma 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-07-20 - Kvartalsrapport 2017-Q2
2017-05-24 - X-dag ordinarie utdelning HNSA 0.00 SEK
2017-05-23 - Årsstämma
2017-04-26 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-11-21 - Extra Bolagsstämma 2016
2016-11-09 - Kvartalsrapport 2016-Q3
2016-07-21 - Kvartalsrapport 2016-Q2
2016-05-11 - Årsstämma
2016-04-28 - X-dag ordinarie utdelning HNSA 0.00 SEK
2016-04-27 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-10-28 - Kvartalsrapport 2015-Q3
2015-08-25 - Kvartalsrapport 2015-Q2
2015-04-17 - X-dag ordinarie utdelning HNSA 0.00 SEK
2015-04-16 - Årsstämma
2015-04-16 - Kvartalsrapport 2015-Q1
2015-02-05 - Bokslutskommuniké 2014
2014-07-25 - Kvartalsrapport 2014-Q2
2014-06-04 - X-dag ordinarie utdelning HNSA 0.00 SEK
2014-06-03 - Årsstämma
2014-03-05 - Extra Bolagsstämma 2014
2014-02-05 - Bokslutskommuniké 2013
2013-07-25 - Kvartalsrapport 2013-Q2
2013-05-07 - X-dag ordinarie utdelning HNSA 0.00 SEK
2013-05-06 - Årsstämma
2013-02-07 - Bokslutskommuniké 2012
2012-09-28 - Kapitalmarknadsdag 2012
2012-07-26 - Kvartalsrapport 2012-Q2
2012-05-14 - Årsstämma
2012-02-09 - Bokslutskommuniké 2011
2012-01-09 - Extra Bolagsstämma 2011
2011-07-28 - Kvartalsrapport 2011-Q2
2011-05-12 - Årsstämma
2011-05-06 - X-dag ordinarie utdelning HNSA 0.00 SEK
2010-04-30 - X-dag ordinarie utdelning HNSA 0.00 SEK
2010-02-10 - Bokslutskommuniké 2009
2009-07-30 - Kvartalsrapport 2009-Q1
2009-05-12 - Kvartalsrapport 2009-Q2
2009-04-30 - X-dag ordinarie utdelning HNSA 0.00 SEK
2009-04-29 - Årsstämma

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Hansa Biopharma är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för autoimmuna sjukdomar och transplantation. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en närvaro i Europa och Nordamerika. Hansa Biopharma grundades 2007 och har sitt huvudkontor i Lund.
2020-06-25 17:30:00

The positive opinion marks an important milestone as the Company prepares its transformation into a commercial stage biopharmaceutical company. 

Lund, Sweden June 25, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending conditional approval of Idefirix[TM] (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. 

"We are very excited to receive a positive opinion from the CHMP. This brings hope to the thousands of highly sensitized patients across Europe waiting for a life-saving kidney transplant and takes Hansa Biopharma one important step closer to becoming a commercial stage biopharmaceutical company" says Søren Tulstrup, President and CEO of Hansa Biopharma.

"Today's decision by the CHMP further serves to validate the potential of Hansa Biopharma's proprietary drug development engine to develop approvable immunomodulatory drug candidates for rare and serious diseases and comes at a time when we are significantly expanding our activities into autoimmune diseases, gene therapy and oncology". 

The Marketing Authorization Application for imlifidase in kidney transplant was accepted for review by the European Medicines Agency on Feb. 28, 2019 based on data from four completed phase 2 studies across Sweden, France and the United States. Imlifidase met all primary and secondary endpoints in each study.

Imlifidase was supported through EMA's PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. Imlifidase was granted eligibility to PRIME in May 2017.

In the US, following overall agreement with the FDA, Hansa Biopharma submitted a study protocol to the FDA on June 17, 2020. The randomized, controlled clinical study is planned to be initiated in Q4 this year and could support a future BLA submission in the US by 2023, as communicated earlier. The Company aims to recruit 45 highly sensitized patients at 10-15 centers in the US for this study. 

Clinical pipeline 
Enrollment in the investigator initiated Anti-GBM study was completed at the end of January 2020 and the first data read-out is expected in the third quarter of 2020 as previously guided.

In the AMR and GBS phase 2 studies, 4 of the targeted 30 patients have been treated with imlifidase in the respective studies. Enrollment in the AMR and GBS studies is expected to be completed in H1 2021 and H2 2021, respectively, as communicated previously. 
About imlifidase
Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansa has also reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. and has three ongoing phase 2 trials in autoimmune diseases and post-transplant indications.